Immune Therapeutics Signs Binding Letter of Intent to Acquire Chinese CAR-T Technology and Clinical Data
April 21 2016 - 9:00AM
Marketwired
Immune Therapeutics Signs Binding Letter of Intent to Acquire
Chinese CAR-T Technology and Clinical Data
ORLANDO, FL-(Marketwired - Apr 21, 2016) - Immune Therapeutics
Inc. (OTCQB: IMUN) today announced that they have signed a binding
Letter of Intent to acquire Chinese Chimeric Super Antigen Receptor
T cell (CAR-T) cocktail therapy, Immuno-Oncology patents (pending),
manufacturing technology, and clinical data of the aforementioned
therapies from Super-T Cell Cancer Company ("STCC") a newly formed
corporation.
"This CAR-T cell technology licensing further accelerates IMUN's
growth in the Immuno-Oncology field as we evaluate paths to
commercialization both in China and other Emerging Markets,"
commented Christopher Pearce, Chief Operating Officer.
CAR-T cell therapy involves engineering cancer patients' own
immune cells to recognize and attack cancer tumors. CAR-T
therapy has great potential to improve patient-specific cancer
therapy in a profound way. Numerous studies have implicated
regulatory T cells as key mediators in the creation of an
immunosuppressed microenvironment that enables tumors to escape
attack by the host immune system. The Super CAR-T Cocktail
therapy has shown promise in early human clinical trials for the
treatment of blood cancer, renal, cervical and hepatic cancer.
"We are very impressed by the quality of the work done by
Professor Shan and his team, and are excited by the safe and
efficacious profile of this novel CAR-T cocktail therapy for
cancerous diseases. This is the beginning of a long-term
strategic partnership between IMUN and STCC. Together, we will
expeditiously continue our quest in developing more affordable,
safer, and more effective cancer immunotherapy programs," said
Noreen Griffin, Chief Executive Officer of Immune Therapeutics,
Inc.
The need in China for new affordable therapies is critical. It
is predicted that there will be about 4,292,000 newly diagnosed
invasive cancer cases in 2016, corresponding to almost 12,000 new
cancer diagnoses on average each day. IMUN believes that once
approved it could capture 5% of the market in the first year.
Forward Looking Statements
This release contains forward-looking statements. Actual results
may differ from those projected due to a number of risks and
uncertainties, including, but not limited to the possibility that
some or all of the matters and transactions considered by Immune
Therapeutics may not proceed as contemplated, and by all other
matters specified in Immune Therapeutics' filings with the
Securities and Exchange Commission. These statements are made based
upon current expectations that are subject to risk and uncertainty.
Immune Therapeutics does not undertake to update forward-looking
statements in this news release to reflect actual results, changes
in assumptions or changes in other factors affecting such
forward-looking information. Assumptions and other information that
could cause results to differ from those set forth in the
forward-looking information can be found in the Immune
Therapeutic's filings with the Securities and Exchange Commission,
including its recent periodic reports.
About Immune Therapeutics, Inc.:
Immune Therapeutics, Inc. [F/K/A TNI Biotech, Inc.] is a
biotechnology company working to combat chronic, life-threatening
diseases through the activation and modulation of the body's immune
system using our patented immunotherapy. Its products and
immunotherapy technologies are designed to harness the power of the
immune system to improve the treatment of cancer, infections such
as HIV/AIDS, chronic inflammatory diseases, and autoimmune
diseases.
Its proprietary technology, therapies, and patents include the
treatment of a wide range of cancers. The most advanced clinical
programs involve immunotherapy with met-enkephalin (MENK)
(sometimes referred to as opioid growth factor) and our Low Dose
Naltrexone product (LDN) or Lodonal, which have been shown to
stimulate the immune system even in patients with advanced
cancer.
Even though management considers any condition that results in
altered-immune response a target for investigation, we will most
likely pursue additional investigations for MENK and LDN as
valuable candidates in the treatment of autoimmune states such as
rheumatoid arthritis and multiple sclerosis; as an adjunct in
cancer patients undergoing chemotherapy, radiation treatments or
surgery; and as a complement to antibiotics in the treatment of a
variety of infectious diseases, including patients with HIV/AIDS,
in combination with retroviral drug therapy.
CONTACT INFORMATION Amato and Partners, LLC Investor Relations
Counsel 90 Park Avenue. 17th Floor New York, NY 10016
admin@amatoandpartners.com
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Jul 2023 to Jul 2024